Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study

OBJECTIVES: Describe and compare the risk of cardiovascular and non-cardiovascular mortality in patients whose antidiabetic therapy is modified to include pioglitazone compared with an alternative antidiabetic medication at the same stage of disease progression. RESEARCH DESIGN AND METHODS: This exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Strongman, Helen, Christopher, Solomon, Majak, Maila, Williams, Rachael, Bahmanyar, Shahram, Linder, Marie, Heintjes, Edith M, Bennett, Dimitri, Korhonen, Pasi, Hoti, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783110/
https://www.ncbi.nlm.nih.gov/pubmed/29379607
http://dx.doi.org/10.1136/bmjdrc-2017-000481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783110/
https://www.ncbi.nlm.nih.gov/pubmed/29379607
http://dx.doi.org/10.1136/bmjdrc-2017-000481

Ejemplares similares